- Visibility 20 Views
- Downloads 13 Downloads
- Permissions
- DOI 10.18231/j.ijpo.10788.1620688092
-
CrossMark
Study of lesions of prostate after surgery and its correlation with PSA level and expression of p504s IHC marker in malignant lesions of prostate
- Author Details:
-
Geetika Agarwal *
-
Deepak Mittal
-
Deepali Gupta
-
Hemant Kumar
-
Divya Pursnani
-
Tanmeet Kaur
-
Asmita .
Geetika Agarwal *
Background: Prostate lesions encompass a spectrum of benign and malignant pathologies, with prostate-specific antigen (PSA) serving as a key biomarker in their evaluation. Immunohistochemical (IHC) markers, such as α-methylacyl-CoA racemase (P504S), have emerged as adjuncts in distinguishing malignancies. This study aims to analyse post-surgical prostate lesions, correlate histopathological findings with PSA levels, and assess the expression of P504S in malignant cases.
Materials and Methods: This hospital-based observational study was conducted in 150 prostate specimens which were obtained post-surgery. After the thorough analysis. Histopathological classification was performed and PSA levels were analysed in relation to lesion type. IHC staining for P504S was conducted in malignant cases to determine its diagnostic utility. Statistical analysis was applied to assess correlations between PSA levels, histological diagnosis, and P504S expression.
Results: We analysed a total of 150 cases, with the highest proportion (48.67%) in the 60–70 years age group and a mean age of 67.40 ± 8.69 years. Non-neoplastic lesions were predominant (94%), while neoplastic cases accounted for 6%. Benign lesions were most common in the 60–70 years group, whereas malignancy was more frequent in individuals over 80 years (44.44%). Retention of urine (30%) was the most common symptom. Histopathological analysis showed benign prostatic hyperplasia (41.33%) as the most frequent diagnosis, followed by chronic nonspecific prostatitis (25.33%) and adenocarcinoma (6%). PSA levels above 20 ng/mL were predominantly associated with malignancy. Higher Gleason scores (9 and 8) were common, indicating aggressive tumors. A significant correlation was observed between age, PSA levels, and Gleason’s score (p < 0.0001).
Conclusion: Our study concludes that, histopathological evaluation remains the gold standard for diagnosing prostate lesions, while PSA serves as a useful but non-specific biomarker. P504S IHC staining enhances the diagnostic accuracy for malignancy. The combination of PSA levels with histopathological and IHC findings improves the stratification of prostate lesions, easing early and accurate diagnosis.
References
- Rifkin MD. Ultrasound of the Prostate. 2nd ed. Philadelphia: Lippincott-Raven; 1997. p. 3–14.
- Marx FJ, Karenberg A. History of the term prostate. Prostate. 2009;69(2):208–13. https://doi.org/10.1002/pros.20871
[Google Scholar] - Goddard JC. The history of the prostate, part one: say what you see. Trends Urol Mens Health. 2019;10(1):28–30. 340 Agarwal et al. / Indian Journal of Pathology and Oncology 2025;12(3):335–340
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN
- Int J Cancer. 2010;127(12):2893–917. https://doi.org/10.1002/ijc.25516
[Google Scholar] - Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
- Waldron T. A nineteenth-century case of carcinoma of the prostate, with a note on the early history of the disease. Int J Osteoarchaeol. 1997;7(3):241–7. https://doi.org/10.1002/(SICI)1099-
[Google Scholar] 1212(199705)7:3<241::AID-OA354>3.0.CO;2-2. - Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017;28(11):2658–69. https://doi.org/10.1093/annonc/mdx348
[Google Scholar] - Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013;5(6):318–29. https://doi.org/10.1177/1756287213495915
[Google Scholar] - Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, editors. Campbell's Urology. 6th ed. Vol 2. Philadelphia: WB Saunders; 1992. p. 1159–
- Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71. https://doi.org/10.1016/j.eururo.2010.10.039
[Google Scholar] - Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2(5):389–96. https://doi.org/10.1038/nrc801
[Google Scholar] - Herr HW. The enlarged prostate: a brief history of its surgical treatment. BJU Int. 2006;98(5):947–52. https://doi.org/10.1111/j.1464-410X.2006.06397.x
[Google Scholar] - Young HH. Four cases of radical prostatectomy. Johns Hopkins Bull. 1905;16:315.
- Aronovitz JN. A century of brachytherapy (from the prostate’s perspective). In: Devlin PM, editor. Brachytherapy: Applications and Techniques. 2nd ed. New York, NY: Demos Medical Publishing, LLC; 2015. p. 1–36.
- Evans AJ. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol. 2003;56(12):892–7. https://doi.org/10.1136/jcp.56.12.892
[Google Scholar] - Gudeli V, Pallivilla UR, Chilkuri S, Reddi H, Raavi K, Thota A. Utility of alpha-methyl acyl-CoA racemase marker in prostatic adenocarcinomas. Natl J Lab Med. 2021;10(4):PO05–8. https://doi.org/10.7860/NJLM/2021/47043:2525
[Google Scholar] - Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220–6.
- Coakley FV, Hricak H. Radiologic anatomy of the prostate gland: a clinical approach. Radiol Clin North Am. 2000;38(1):15–29. https://doi.org/10.1016/s0033-8389(05)70147-0
[Google Scholar]